Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;11(4):675-82.
doi: 10.1111/j.1474-9726.2012.00832.x. Epub 2012 Jun 4.

Rapamycin slows aging in mice

John E Wilkinson  1 , Lisa Burmeister, Susan V Brooks, Chi-Chao Chan, Sabrina Friedline, David E Harrison, James F Hejtmancik, Nancy Nadon, Randy Strong, Lauren K Wood, Maria A Woodward, Richard A Miller
Affiliations

Rapamycin slows aging in mice

John E Wilkinson et al. Aging Cell. 2012 Aug.

Abstract

Rapamycin increases lifespan in mice, but whether this represents merely inhibition of lethal neoplastic diseases, or an overall slowing in multiple aspects of aging is currently unclear. We report here that many forms of age-dependent change, including alterations in heart, liver, adrenal glands, endometrium, and tendon, as well as age-dependent decline in spontaneous activity, occur more slowly in rapamycin-treated mice, suggesting strongly that rapamycin retards multiple aspects of aging in mice, in addition to any beneficial effects it may have on neoplastic disease. We also note, however, that mice treated with rapamycin starting at 9 months of age have significantly higher incidence of testicular degeneration and cataracts; harmful effects of this kind will guide further studies on timing, dosage, and tissue-specific actions of rapamycin relevant to the development of clinically useful inhibitors of TOR action.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Incidence of liver degeneration (males only), myocardial nuclear atypia, endometrial hyperplasia (females only), and adrenal tumor in young, old, and rapamycin-treated mice. Group sizes were as follows: young, old, and Rapa-Low, 15 of each sex; Rapa-Mid 14 females and 12 males; Rapa-High, 13 females and nine males. Fisher's Exact Test was used to evaluate the significance of age effects (young vs. old untreated), to compare Rapa (all doses) vs. old (untreated), or to compare old untreated vs. Rapa-high as indicated in the figure panels. Cuzick's nonparametric test for trends (Cuzick, 1985) was used to evaluate significance of differences among the four groups of old mice at rapamycin doses (zero, low, mid, or high).
Fig. 2
Fig. 2
Incidence of adrenal hyperplasia, adrenal telangectasia, ovarian cyst (females only), thyroid cold follicles, and lung tumor in young, old, and rapamycin-treated old mice (pooled across rapamycin doses). The bracket in each figure indicates a significant difference between young and untreated old mice by Fisher's Exact Test.
Fig. 3
Fig. 3
Maximum tangent modulus (left) and hysteresis area (right) for tibialis anterior tendons. Bars show mean ± SEM for N = 6 young, 9 old, and 17–20 old rapamycin-treated mice. Young values differed from old at P = 0.002 for each endpoint by t-test. Old differed from rapamycin treatment group at P = 0.036 for maximum tangent modulus and at P < 0.001 for hysteresis area.
Fig. 4
Fig. 4
Cataract severity in mice evaluated by slit lamp examination at 20 months of age. Each eye was scored on a scale of 0–3, and the mean value of the left and right eye was used as the index of severity for each mouse. Bars shown mean ± SEM for groups of 25–29 female mice or 17–30 male mice. Significance of the trend among four groups of 20-month-old mice (old, Rapa-low, Rapa-mid, and Rapa-high) was evaluated by the nonparametric method of Cuzick (Cuzick, 1985).
Fig. 5
Fig. 5
Testicular degeneration in males. Group sizes as in Fig. 1, with statistical evaluation as in (Cuzick, 1985).
Fig. 6
Fig. 6
Age-associated decline of spontaneous in-cage activity, calculated as a change score (× 10–3) for each mouse tested at both 7 and 18 months of age. Bars show means ± SEM, and asterisks indicate significant effects of rapamycin treatment at P < 0.05, as estimated using a two-factor anova with Site (UT, UM, TJL) and Rx (rapamycin or untreated) as the predictor variables.
Fig. 7
Fig. 7
Rapamycin levels in blood of mice tested at age 8–9 months after consumption of rapamycin for 5 months. Each symbol shows an individual mouse, and horizontal bars indicate means.
See this image and copyright information in PMC

Similar articles

  • Rapamycin extends murine lifespan but has limited effects on aging.
    Neff F, Flores-Dominguez D, Ryan DP, Horsch M, Schröder S, Adler T, Afonso LC, Aguilar-Pimentel JA, Becker L, Garrett L, Hans W, Hettich MM, Holtmeier R, Hölter SM, Moreth K, Prehn C, Puk O, Rácz I, Rathkolb B, Rozman J, Naton B, Ordemann R, Adamski J, Beckers J, Bekeredjian R, Busch DH, Ehninger G, Graw J, Höfler H, Klingenspor M, Klopstock T, Ollert M, Stypmann J, Wolf E, Wurst W, Zimmer A, Fuchs H, Gailus-Durner V, Hrabe de Angelis M, Ehninger D. Neff F, et al. J Clin Invest. 2013 Aug;123(8):3272-91. doi: 10.1172/JCI67674. Epub 2013 Jul 25. J Clin Invest. 2013. PMID: 23863708 Free PMC article.
  • Rapamycin extends life- and health span because it slows aging.
    Blagosklonny MV. Blagosklonny MV. Aging (Albany NY). 2013 Aug;5(8):592-8. doi: 10.18632/aging.100591. Aging (Albany NY). 2013. PMID: 23934728 Free PMC article.
  • Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice.
    Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV. Anisimov VN, et al. Cell Cycle. 2011 Dec 15;10(24):4230-6. doi: 10.4161/cc.10.24.18486. Epub 2011 Dec 15. Cell Cycle. 2011. PMID: 22107964
  • Is Rapamycin a Dietary Restriction Mimetic?
    Unnikrishnan A, Kurup K, Salmon AB, Richardson A. Unnikrishnan A, et al. J Gerontol A Biol Sci Med Sci. 2020 Jan 1;75(1):4-13. doi: 10.1093/gerona/glz060. J Gerontol A Biol Sci Med Sci. 2020. PMID: 30854544 Free PMC article. Review.
  • Koschei the immortal and anti-aging drugs.
    Blagosklonny MV. Blagosklonny MV. Cell Death Dis. 2014 Dec 4;5(12):e1552. doi: 10.1038/cddis.2014.520. Cell Death Dis. 2014. PMID: 25476900 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahuja P, Sdek P, MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol. Rev. 2007;87:521–544. - PMC - PubMed
    1. Amador-Noguez D, Dean A, Huang W, Setchell K, Moore D, Darlington G. Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell. 2007;6:453–470. - PMC - PubMed
    1. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV. Rapamycin extends maximal lifespan in cancer-prone mice. Am. J. Pathol. 2010;176:2092–2097. - PMC - PubMed
    1. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011;10:12–15. - PubMed
    1. Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle. 2006;5:2087–2102. - PubMed

Publication types

MeSH terms